A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma - Wikidata - wikimedia - TriplyDB

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

http://www.wikidata.org/entity/Q33342339

about

Adoptive immunotherapy for cancer: building on success Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma Eradication of melanomas by targeted elimination of a minor subset of tumor cells Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes T-cell clonotypes in cancer Adoptive T cell therapy: Addressing challenges in cancer immunotherapy Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Advances in the treatment of metastatic melanoma: adoptive T-cell therapy Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity T-cell receptor gene therapy--ready to go viral?Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells CSPG4: a prototype oncoantigen for translational immunotherapy studies.Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.T cells take aim at cancer How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells.CD8+ T-cell memory in tumor immunology and immunotherapy.Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model.Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy Programming CD8+ T cells for effective immunotherapy.Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients.The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.Adoptive T cell immunotherapy for cancer.Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma.Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.

P2860

Q24546258-4F2D3E12-0A9C-4826-B8ED-2B2FFB88EA99 Q24548019-06DB05EA-AEEB-410C-940A-C50C8CA5B1D2 Q24624761-D0171A70-F23E-441F-84D1-B2523F707AFF Q24676216-CFAA0BBD-DE65-4A91-A4FE-B678390C9BFB Q24803891-AFDC3F23-6C41-4456-B964-4FF0348854BA Q24805804-8B34F0B6-FEE9-4C30-B2F5-44041D288988 Q26745444-42B2EA7B-30A5-4F25-9E75-4CA8C141C9A5 Q26751018-18C13EAE-85C2-4D0D-ABA3-599C6F0D9C6D Q27002575-7552C27C-E73F-4B6D-8A68-5E72812318FA Q27027803-B571F313-E2FA-4F5B-A6F3-3B4FDD0904F0 Q27680213-ABA3331E-8AEB-4D32-B78E-5112CF92B067 Q28081611-6837DEA1-AADA-467B-98B3-77930C56A922 Q33261122-9CD1B39C-0C98-44F4-8AF2-D31A18C8D612 Q33716478-AA37BB46-494A-4573-A569-AAEF2EEB3692 Q33791998-A9A97126-0523-40A8-A43B-9C79E5802386 Q33831940-9F75D6BC-7A1E-4F14-B40F-564A1ACC18A6 Q33862585-C82CB0A5-CC9D-4239-B192-66135C82B6C2 Q34034408-DFC14767-2940-4243-959D-4373B3E4F756 Q34216825-E07A573D-D160-4D4E-926E-438E1680FB06 Q34279672-2ABCBD95-FCA0-4570-A6D3-96C6C1393AD2 Q34414412-4DE719EB-2896-4262-BC2F-474EE447EFE2 Q34418112-F790A12B-D1EC-4000-938B-A5A860FD574E Q34422330-1D73727E-7E15-4B7A-B770-D6EEA4761FAA Q34458364-D19FC930-48F1-4690-9707-B8D1BB3BF37C Q34501316-F2F9D40A-E233-4B20-A7B8-10428C21E954 Q34657644-0AFC20C5-1422-4F58-9CEB-66B099C15FA5 Q34669675-59C4FD4F-5C9F-4281-A24D-D2F61AA8AF1F Q34732294-0B70261D-71EA-43E5-AC26-B5A4B0D85F42 Q34768139-2AB6528D-1665-412F-AC08-80F893C26215 Q34770289-FB4AC3A5-5DA1-47B5-ABC9-7D3944937BAE Q34795354-CC83DA78-3694-4D19-AB36-E9B82768EC60 Q34823783-5F636AD4-CC70-40AC-B4CC-319EBBBEC8EF Q34976602-815480F7-4076-4EF6-B830-62AAEB658DBC Q35036640-1AA9992F-3375-442B-8B84-DD021F744E18 Q35044159-7F2BFDF3-4D24-4C9D-8BE6-CE38BEFD8FB6 Q35044333-1E02BD08-1024-42E9-B46C-AB39961026AD Q35081485-74B48830-13CE-4247-A8EF-D08C743EFC35 Q35093647-E5A525AE-29E6-4900-A507-5AF179877BFC Q35115741-CA636460-BB95-4321-A86C-154C5B7D1F59 Q35184110-D01C570E-EA04-4F41-8B84-A874C552A573

P2860

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

http://www.wikidata.org/entity/Q33342339

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

A phase I study of nonmyeloabl ...... ients with metastatic melanoma

@ast

A phase I study of nonmyeloabl ...... ients with metastatic melanoma

@en

type

label

A phase I study of nonmyeloabl ...... ients with metastatic melanoma

@ast

A phase I study of nonmyeloabl ...... ients with metastatic melanoma

@en

prefLabel

A phase I study of nonmyeloabl ...... ients with metastatic melanoma

@ast

A phase I study of nonmyeloabl ...... ients with metastatic melanoma

@en

P1433

Q33342339-6EC7BBAB-4844-4025-B6F7-B495518AF6FB

P1476

Q33342339-56059F3D-61DF-435E-974E-9A6C95E116CE

P2093

Q33342339-0060EF99-E02C-4585-A2DB-9E34743139A5

Q33342339-089868CA-B50D-4D0A-A7EA-45CF53FC62B2

Q33342339-0D6424C0-4949-40E4-90BF-5EFD7E2C29DD

Q33342339-18CAEB5B-0FF9-4CB6-9868-78B77714137E

Q33342339-1E8B36ED-4EB8-47A5-B8F4-58911ECF9B12

Q33342339-3ECD56D1-4DDC-4607-B632-9873FA84EE20

Q33342339-8E0389D9-9DD1-428A-BC01-E97581BFF137

Q33342339-97797C4F-8624-4295-A83B-AF15CC1F5C1D

Q33342339-AD5D4757-F551-4CC7-8D74-DAEB1821EDFB

Q33342339-B23B903C-D525-466F-A35B-5837355E7A42

P2860

Q33342339-07E48ABC-E1DE-4BAF-8356-A1DAE162C559

Q33342339-0E20A483-FC2E-4787-85A8-FFB307801185

Q33342339-145D5BCC-C55A-4B0E-B756-1B84B7C4E906

Q33342339-1CCEE9C2-351B-4B12-9862-CB8F0E21520D

Q33342339-29B3336F-693A-45E1-9A37-8DCAC7A3D991

Q33342339-2D000373-BD31-42F9-984D-91C315463C97

Q33342339-35746B95-C411-4A38-9562-800F59DA425B

Q33342339-47CFA655-C093-46E2-83B1-3A75A239489C

Q33342339-5CE3A88F-3176-4656-AE57-7FE1C906C40A

Q33342339-5FDE98B2-09E1-47F2-B395-6A3745BDB740

P304

Q33342339-72D17831-C054-4AB2-8801-772CF6577C6A

P31

Q33342339-94E47268-132E-4982-92A0-A60E438038B9

P356

Q33342339-83F44F9B-E49D-4411-A3FA-D6E8076C41A0

P433

Q33342339-F87AD44A-717B-492D-A7CE-FCD2106290E7

P478

Q33342339-398710E0-3F48-4CDD-9A4D-F896A6910C17

P577

Q33342339-BED506B4-1560-4CDC-A734-B33822B14DAF

P5875

Q33342339-79E5F4F5-E74A-499B-88DC-6440D3183231

P698

Q33342339-8B192755-8700-4B16-BDB0-17591F5B1752

P921

Q33342339-0791F14D-26A3-4210-9CFB-96FA64425B43

P932

Q33342339-F2B962B3-EBFE-4B5B-9739-44E977052A39

P356

00002371-200205000-00007

P1433

Journal of Immunotherapy

P1476

A phase I study of nonmyeloabl ...... ients with metastatic melanoma

@en

P2093

Azam Nahvi

http://www.w3.org/2001/XMLSchema#string

Claudia A Seipp

http://www.w3.org/2001/XMLSchema#string

Donald E White

http://www.w3.org/2001/XMLSchema#string

Douglas J Schwartzentruber

http://www.w3.org/2001/XMLSchema#string

Francesco M Marincola

http://www.w3.org/2001/XMLSchema#string

James C Yang

http://www.w3.org/2001/XMLSchema#string

John R Wunderlich

http://www.w3.org/2001/XMLSchema#string

Kathleen E Morton

http://www.w3.org/2001/XMLSchema#string

Linda Rogers-Freezer

http://www.w3.org/2001/XMLSchema#string

Mark E Dudley

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.

A listing of human tumor antigens recognized by T cells.

Interleukin-7: master regulator of peripheral T-cell homeostasis?

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells.

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.

Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

P304

243-251

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00002371-200205000-00007

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11369811

http://www.w3.org/2001/XMLSchema#string

P698

12000866

http://www.w3.org/2001/XMLSchema#string

P921

P932

2413438

http://www.w3.org/2001/XMLSchema#string